Sevabertinib for HER2+ lung cancer
Sevabertinib has been granted accelerated approval to treat adult patients with unresectable or metastatic non‑squamous non‑small cell lung cancer (NSCLC) whose tumors have HER2 mutations and who have received prior systemic therapy.
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to sevabertinib for the treatment of adult patients with unresectable or metastatic non‑squamous non‑small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) mutations and who have received prior systemic therapy.
This approval represents a new therapeutic option for patients with the rare HER2‑mutated NSCLC subtype, potentially improving outcomes and expanding treatment choices.
Bizonyítékszint: Megerősített klinikai bizonyíték. Több vagy erősebb humán vizsgálat támogatja.
Kapcsolódó jelek
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT